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ABSTRACT
Introduction: Human T-lymphotropic virus type 1 and 2 (HTLV-1/2) is endemic in 
Brazil, but few studies have investigated the seroprevalence of HTLV and its subtypes 
among blood donors in the capital city Manaus, Amazonas State, Brazil. Aim: To estimate 
the seroprevalence of HTLV-1/2 and to identify circulating subtypes among blood donors in 
Manaus. Materials and Methods: Blood donors (2001-2003) were screened for HTLV-1/2 
antibodies by ELISA. Positive results were confirmed and subtyped by Western blot assays. 
Prevalence rates were calculated and compared with demographic data. Results: Among the 
87,402 individuals screened, 116 (0.13%) were seropositive for HTLV-1/2. A second sample 
(76/116) was collected and retested by HTLV-1/2 ELISA, of which only 41/76 were positive. 
Western blot confirmed HTLV infection in 24/41 retested blood donors [HTLV-1 (n=16), 
HTLV-2 (n=5) and HTLV-untypable (n=3)]. Discussion: HTLV-1 and HTLV-2 are prevalent 
among blood donors in Manaus. However, additional studies are needed to comprehend the 
epidemiology of HTLV-1/2 in Amazonas not only to understand the pathophysiology of the 
disease providing adequate medical assistance, but also to reduce or block virus transmission.
KEYWORDS: HTLV. Blood donors. HTLV subtyping. HTLV1. HTLV2. T-lymphotropic 
virus type 1 and 2. Epidemiology of HTLV infection. Prevalence of HTLV. 
INTRODUCTION
Human T-lymphotropic virus 1 and 2 (HTLV-1 and HTLV-2) are retroviruses 
discovered in the 1980s1,2. It is estimated that at least 10 million people worldwide 
are infected with HTLV-1, with endemic foci in Japan, the Caribbean, South 
America, and Central Africa3. HTLV transmission occurs primarily via the 
following three routes: 1) vertically from mother to child, predominantly through 
breastfeeding4,5; 2) between sexual partners through unprotected intercourse6,7; and 
3) blood transfusion from a HTLV positive donor or sharing or re-use of needles and 
syringes to inject drugs8,9. A number of diseases have been associated with HTLV-1, 
including adult T-cell leukemia–lymphoma (ATLL), myelopathy/tropical spastic 
paraparesis (HAM/TSP)10-13, uveitis, infective dermatitis, and other inflammatory 
disorders14, although most virus carriers remain asymptomatic throughout their 
lives. Brazil is one of the largest endemic areas for HTLV-1 and -2 infections3. 
Seroprevalence rates of HTLV-1/2 in Brazilian blood donors range from 0.04% to 
1.0% depending on the geographic region15. In Manaus capital of the Amazonas 
State, the prevalence of HTLV-1 in first-time blood donors was reported as 0.14% 
(2008-2009)16. However, few studies have tried to identify HTLV subtypes in blood 
donors and the prevalence of HTLV in this population. The aim of this study was 
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to estimate the seroprevalence of HTLV and to identify the 
subtypes among blood donors in Manaus.
MATERIALS AND METHODS
Ethical considerations 
This study was approved by the Research Ethics 
Committee of Fundação Hospitalar de Hematologia e 
Hemoterapia do Amazonas (FHEMOAM), in accordance 
with the Brazilian law, which complied with the Declaration 
of Helsinki. All the study participants signed an informed 
consent prior to enrolment.
Patient information
Individuals donating blood at FHEMOAM, Manaus, 
Amazonas, were recruited for the study between August 
2001 and August 2003. A questionnaire was used to 
collect individual information (age, gender, marital status, 
educational level, first time or regular donor).
Serological analysis
Blood donors were screened for antibodies against 
HTLV-1/2 by using an enzyme-linked immunosorbent 
assay (ELISA-Murex HTLV 1, GE 80/81, + 2, Murex 
Diagnostics). Positive samples were then confirmed by 
Western blot (HTLV BLOT 2.4, Genelabs Diagnostics®, 
Singapore), following the manufacturer’s instructions.
Statistics
Statistical analysis used the Chi-square or the Fisher exact 
test if the expected frequencies were less than five. A p-value 
of less than 0.05 was considered statistically significant. 
Analyses were performed using the Epi info 6 software.
RESULTS
A total of 87,402 blood donors were screened by HTLV-
1/2 ELISA between August 2001 and August 2003. A total 
of 116 individuals were tested positive with a seroprevalence 
of 0.13% in the primary screening (Figure 1). However, 
only 76/116 (65.5%) volunteered to participate in the 
confirmatory test. On retesting, only 41/76 individuals 
were found to be positive by HTLV-1/2 ELISA, positive 
samples were then tested by Western blot (WB) to confirm 
diagnoses and to identify the HTLV subtype. According 
to the WB assay, three samples were indeterminate; 14 
samples were negative and 24 were positive for HTLV. 
Among the 24 positive samples, 16 were HTLV-1, five were 
HTLV-2 positive and three samples were HTLV positive, 
but untypable (Figure 1). 
Demographic and epidemiologic data of HTLV-
confirmed samples are shown in Table 1. Average age of 
positive blood donors was 35.3 ± 11.5 years; 41.6% (n=10) 
of positive individuals were women. Moreover, 83.33% 
of positive individuals were first-time blood donors and 
62.5% identified themselves as married. Among the HTLV-
confirmed individuals, 16.6% (n=4) reported transfusion 
history and 54.2% described having had multiple sex 
partners along their entire lives (data not shown).
DISCUSSION
This is the first cross-sectional study to demonstrate the 
presence of HTLV-1 and HTLV-2 among blood donors in 
Manaus, Amazonas. Previous studies have only detected 
HTLV-1 in blood donors from Manaus16,17. In this study, 
the overall seroprevalence of HTLV 1/2 was 0.13% 
(2001-2003). In 1993, HTLV-1 prevalence in 1,200 blood 
donors from Manaus was 0.08%17. In addition, Catalan-
Soares et al.15 reported a HTLV 1/2 seroprevalence of 0.53% 
between 1995 and 2000, whereas, prevalence of HTLV-1 
was estimated to be 0.14% in first-time blood donors 
(2008 to 2009)16. On other hand, HTLV infection was 
absent in pregnant women (n=674)18 and individuals with 
dermatological disease (n=1,200)16 in Manaus. Our results 
are in accordance with the above studies as we found a low 
HTLV-1/2 seroprevalence among blood donors in Manaus. 
Besides, seroprevalence of HTLV-1/2 in blood donors 
has been among the highest in other Northern States of 
Brazil like Amapá (0.71%) and Pará (0.91%) compared to 
Amazonas15, which might be explained by the phenomenon 
of clustering of HTLV infection in some populations3,19. 
Presence of a considerable number of HTLV-2 positive 
individuals in our study can be explained by the fact that 
a significant number of HTLV positive individuals were 
indigenous descendants. Several researchers have shown 
that HTLV-2 is predominant among Brazilian indigenous 
groups, with an area of high endemicity in the Amazon 
region20,21. Moreover, HTLV-2 infections in non-indigenous 
populations have been documented among blood donors in 
urban areas of the Amazon region of Brazil22,23. 
Furthermore, in this study, the prevalence of HTLV 
infection in married individuals was higher (62.5%) 
compared to single individuals (37.5%), which needs to 
be confirmed in a larger population. For transmission of 
HTLV by sexual route, a higher frequency of exposure 
has been described, which may be a reason for the higher 
transmission rates between married individuals7. In addition, 
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Table 1 - Demographic and epidemiologic data for HTLV-confirmed blood donors
Total 
(n=41)
Positive 
(n=24)
Negative 
(n=14)
Undetermined 
(n=3)
p value
Age in years 35.3 ±11.5 (18 – 57)
Female n (%) 11 (26.82%) 10 (41.6%) 1 (7.14%) 0.0500
Maritual status Married 24 (41.46%) 15(62.5%) 7 (50%) 2 (66.66%) 0.6800
Single 17 (58.53%) 9 (37.5%) 7 (50%) 1 (33.33%)
Descendants Indigenous 27 (65.85%) 15 (62.5%) 10 (71.40%) 2 (66.66%)
Japanese 1 (2.43%) 1 (4.16%)
Others 13 (31.70%) 8 (33.33%) 4 (28.60%) 1 (33.33%)
Education Elementary School 14 (34.14%) 11 (45.83%) 3 (21.42%) 0.3199
High school 25 (60.97%) 12 (50.00%) 10 (71.42%) 3 (100%)
Higher education 2 (4.87%) 1 (4.17%) 1 (7.14%) 0
Native Amazonas state Yes 29 (70.70%) 15 (62.5%) 11 (78.57%) 3 (100%) 0.5052
Blood donor First time 24 (41.46%) 20 (83.33%) 2 (14.28%) 2 (66.66%) 0.0001
Repeat 17 (58.53%) 4 (16.66%) 12 (85.72%) 1 (33.33%)
Figure 1 - Serological screening and confirmation of HTLV-1 and HTLV-2 positive blood donors - Flowchart depicts an approach 
for detection and confirmation of HTLV infection in blood donors
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first-time blood donors had a higher prevalence of HTLV 
infection compared to regular blood donors. This confirms 
that regular blood donors are perceived to be less risky or 
safer than first-time blood donors. A higher prevalence of 
HTLV was observed in women, however, we did not observe 
any statistically significant association between age and sex 
in HTLV1/2 infection. Nevertheless, in most endemic areas, 
HTLV-1 prevalence has been shown to increase with age and 
to be higher in females24. Besides, absence of a molecular 
test to identify and confirm the circulating strains of HTLV-1 
and HTLV-2 has been one of the greater limitations of this 
study due to unavailability of samples. Nevertheless, using 
serological tools, we conclusively demonstrated circulation 
of HTLV-1 and HTLV-2 in blood donors in Amazonas. 
In response to the epidemiological situation, one of the 
major recommendations by the Global Virus Network’s 
Task Force on HTLV is an improved understanding of 
HTLV epidemiology in diverse populations, which not 
only will stimulate basic research in identifying disease 
biomarkers, but will also unravel mechanisms of viral 
infectivity, persistence, replication and pathogenesis to 
open insights into novel treatments25. In this context, 
further studies are needed to understand the epidemiology 
of HTLV-1/2 in Amazonas not only to estimate the disease 
burden, but also to create a mechanism for continued follow-
up and to reduce or block intra-familial transmission. 
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